Objectives: The survival rates of patients long-term dialysis are increasing with the improvement of the survival rates of dialysis patients in general. Although arteriovenous fistula (AVF) is usually the first choice for vascular access because of its long patency rate and low complication profile, there are sometimes cases in which it is difficult to perform AVF because of poor vascular conditions in elderly patients or in those on long-term dialysis. In such cases, an artificial vascular graft (AVG) must be implanted. There are various types of AVG. We used 2 types of AVG, both of which can be punctured in the early stage and campaired their patency. Methods: From July 2006 to November 2009, we implanted Thoratec or Advanta polytetrafluoroethylene (PTFE) grafts in patients with chronic renal failure and analyzed their patency. AVG implant surgery was performed under general anesthesia. After passing the AVG under the skin, the end of the graft was anastomosed to the vessel using a 5-0 polypropylene or CV-5 ePTFE graft in a continuous fashion. Results: We implanted a total of 66 grafts (39 Thoratec and 27 Advanta). The mean age did not significantly differ between the 2 groups. In the Thoratec group, 18 patients died and 2 were lost during follow up in the Thoratec group, and 9 died in the Advanta group. We calculated the cumulative patency rates using the Kaplan-Meier method including primary (problem-free) and secondary (revised or functional) patency rates. At 1 and 2 years, primary patency rates were 37.2% and 23.2%, respectively, in the Thoratec group and 72.5% and 60.4% respectively, in the Advanta group (p
=0.0098). At 1 and 2 years, the secondary patency rates were 67.5% and 67.5%, respectively, in the Thoratec group and 96.3% and 96.3% respectively, in the Advanta group (p
=0.0118). The mediam interval between surgery and first graft implantation was 3 days in the Thoratec group and 9 days in the Advanta group. The Thoratec graft could be punctured earlier than the Advanta graft (P
=0.0044). Conclusions: The Advanta was superior to the Thoratec in both primary and secondary patency.
View full abstract